Parekh also discussed the use of mogamulizumab, an anti-CCR4 antibody, in the treatment of secondary T-cell lymphoma, underscoring the importance of patient selection and multidisciplinary monitoring. OncLive: How can strategies like drug screening platforms, kill-switch designs, and CHIP mutation surveillance be integrated into managing CAR T-cell therapy complications? These array-type approaches, where we can systematically screen for drugs and give custom therapies, will actually give us a kill switch for the [CAR T-cell therapy], which is not in current [CAR T-cell therapy] designs, but can be very useful, not just for T-cell lymphomas, but potentially other complications such as hemophagocytic lymphohistiocytosis [HLH] and rare neurotoxicity that has also been noted with anti-BCMA [CAR T-cell therapy], so there are broader implications. How should physicians monitor for secondary cancers after CAR T-cell therapy? One is the use of safer kill switches, or [CAR T-cell therapies] that can actually be modulated.